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We report the results of studies related to the fabrication of a palladium nanoparticle decorated-reduced
graphene oxide (Pd@rGO) based electrochemical immunosensor for the label free ultrasensitive
detection of the prostate-speciﬁc antigen (PSA), a prostate cancer biomarker. The synergistic
electrochemical activities of Pd and rGO result in an enhanced electron transfer used for the
development of an ultrasensitive immunosensor. A facile approach was developed for the in situ
synthesis of Pd@rGO using ascorbic acid as the reducing agent which enables the simultaneous
reduction of both Pd+2 and GO into Pd nanoparticles and rGO, respectively. XRD, FTIR, SEM and TEM
investigations were carried out to characterize the Pd@rGO material. A thin ﬁlm of nanostructured
Pd@rGO was electrophoretically deposited on an ITO coated glass electrode that was subsequently
functionalized with anti-PSA antibodies. The electrochemical sensing results of the proposed
immunosensor showed a high sensitivity {28.96 mA ml ng1 cm2}. The immunosensor is able to detect
PSA at concentrations as low as 10 pg ml-1. The simple fabrication method, high sensitivity, good
reproducibility and long term stability with acceptable accuracy in human serum samples are the main
advantages of this immunosensor.Introduction
Early and accurate diagnosis of cancer is a key challenge for the
successful treatment of the disease. Amongmore than 200 types
of human cancer, prostate cancer has become the second
leading cause of cancer death in males. The prostate-specic
antigen (PSA), a 33 kDa serine protease largely bound to
endogenous protease inhibitors in serum, has been widely
accepted as a biomarker of prostate cancer.1–3 For healthy
males, the PSA concentration level in serum ranges from 0 to
4 ng ml1. Routinely used diagnostic techniques based on
morphological investigations such as magnetic resonance
imaging (MRI) and ultra sonography (USG), have been used foriversity, Varanasi-221005, India. E-mail:
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hemistry 2014the diagnosis of prostate related problems but have not been
found to be suﬃcient for the detection of cancer. On the other
hand, PSA tests measure total PSA levels i.e. the levels of free
and bound PSA secreted by both normal and cancerous glan-
dular cells of prostate,4,5 which plays an important role towards
the detection of cancer. Thus, proper monitoring of total PSA
levels (other than through biopsy) is critical for the evaluation of
the prostate cancer malignancy. Enzyme linked immunosor-
bent assays (ELISAs), uorescence immunoassays,6 chemilu-
minescent assays,7 and time-resolved immunouorometric
assays8,9 have been developed for PSA detection. ELISA is quite a
promising technique but it is time consuming, requires
labeling and is not suﬃcient for sensitive detection if the
biomarker is present in very low concentrations (sub nanogram
to picogram levels). However, methods other than ELISA,
unfortunately, are either harmful to the health, time-
consuming and labor-intensive, or require highly trained
personnel and sophisticated instrumentation. Therefore, there
is a strong need to develop a real-time, high sensitive, and label
free sensing devices which may overcome the drawbacks of
ELISA and the other methods.10,11 In recent years, electro-
chemical biosensors have gained much interest due to their
rapidity, high sensitivity and high signal to noise ratio as well as
their relative inexpensiveness and low reagent consumption. In
addition, electrochemical detection systems can be easily
miniaturized without reducing their analytical performance.RSC Adv., 2014, 4, 2267–2273 | 2267
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View Article OnlineThus, electrochemical detection has emerged as a powerful
technique for the rapid and sensitive detection of biomarkers
even at low concentrations.12
Metal nanoparticles of palladium (Pd) and platinum (Pt),
owing strong electrocatalytic properties, have shown tremen-
dous potential in a wide range of applications, such as in energy
storage, catalysis and in electrochemical sensors.13–15 The elec-
tro-catalytic properties of these nanoparticles are largely inu-
enced by the size and morphology of these materials. In this
regard, a lot of work has been focused on improving the
synthetic control over the size and morphology of these nano-
particles using diﬀerent stabilizing agents.16–18 Dispersing these
nanoparticles on the surface of two dimensional nanomaterials
(without stabilizers) might be a much better approach to access
the excellent properties of these metal nanoparticles.
Graphene oxide (GO) and reduced graphene oxide (rGO)
(derivatives of graphene) are 2-D nanostructures possessing a
high surface area with strong chemical stability that have been
used as a suitable matrix for the synthesis of various metal
nanoparticles.19 Because of their high surface area, GO and rGO
provide the ideal support for the homogeneous dispersion of
metal nanoparticles without aﬀecting their electrochemical
activities.19
Nanostructures of graphene with metal nanoparticles have
expanded the range of applications due to their superior and
even new functional properties via cooperative interactions.
One of such examples is their application as electrode materials
for the development of high performance biosensing devices,
where the enhanced electron transfer leading to an eﬃcient
collection and transfer of electrons at the electrode surface may
be anticipated.
In comparison to Pt nanoparticles, Pd nanoparticles have
been a hot topic of interest due to their better catalytic activity
and lower cost.20–25 First principle calculations have also indi-
cated the strong interaction and binding aﬃnity of Pd nano-
particles and graphene.26 Several methods have been reported
for the synthesis of Pd nanoparticle decorated graphene
sheets27,28 using strong reducing agents. Two parameters of the
nanostructure are crucial for their application towards the
development of high sensitive biosensors: rstly, the electrical
conductivity which is directly related to the signal amplication
and secondly, the content in surface functionalities to achieve
the loading of the maximum amount of biomolecules which
leads to an enhanced sensitivity.
The current study is aimed to develop a single step facile
method for the in situ synthesis of Pd@rGO with an improved
conductivity while maintaining an enough surface function-
ality. Although GO possesses a larger number of oxygen func-
tionalities than rGO, the reduced conductivity of GO in
comparison to rGO restrict its further application as a sensitive
platform for biosensing purposes. Therefore, a material in
between GO and rGO is highly desirable as a high sensitive
platform for biosensing purposes, which could be obtained by
the controlled reduction of GO to rGO. Strong reducing agents
(used in the earlier reported methods) do not meet such a
requirement and this needs to be achieved by the use of a mild
reducing agent. In the current study, ascorbic acid, a mild2268 | RSC Adv., 2014, 4, 2267–2273reductant, is used to achieve the controlled and simultaneous
reduction of Pd+2 and GO to Pd0 and rGO, respectively, in the
same process, to nally obtain Pd@rGO while preserving
the adequate functional groups (for bio-functionalization). The
remained functional groups in Pd@rGO are not only important
for bio-functionalization but play a crucial role towards the
enhanced electron transfer. The synthesized Pd@rGO was
further used for the development of a sensitive platform for the
electrochemical detection of the PSA cancer biomarker.
Materials and methods
Materials
Graphite powder akes (45 mm, >99.99 wt%), Na2PdCl4,
L-ascorbic acid, prostate-specic antigen (PSA) and monoclonal
anti-PSA antibody, bovine serum albumin (BSA), and human AB
type serum (male) were purchased from Sigma-Aldrich Chem-
ical Pvt. Limited, Bangalore, India. All other used chemicals
were obtained from Merck India Pvt. Limited, Mumbai, India.
Synthesis of graphene oxide (GO)
Graphene oxide was synthesized using the improved Hummers
method29 with a slight modication. In brief, 0.0015 kg of
graphite powder was pre-oxidized by reacting it with a mixture
of 40 ml of 98% H2SO4, 5 g K2S2O8 and 5 g of P2O5 for 4 h at
80 C. The resulting suspension was washed with deionized
water (DI) 4–5 times and vacuum dried at 50 C. Further
oxidation was achieved by adding the pre-oxidized graphite to a
mixture of concentrated H2SO4–H3PO4 (v/v:180 : 13) with
constant stirring. Aer 5 min, 9 g of KMnO4 was added to the
mixture and the stirring was continued for 15 h at 50 C .The
reaction was stopped aer about 15 h and the reactants were
allowed to cool at room temperature aer which 200 ml of ice
were poured into the mixture followed by 1.5 ml of H2O2 (30%).
The nematerial was separated from themixture through a U.S.
standard testing sieve of pore size 30 mm. The supernatant was
discarded and the ltrate was subject to centrifugation at
5000 rpm for 3 h. Multiple washings of the sedimented material
were carried out several times with DI water, 30% HCl and
ethanol (100 ml of each) followed by centrifugation and sepa-
ration. The nal sediment was suspended in 100ml of ether and
ltered through a PTFE membrane with a pore size of 0.45 mm.
The obtained semi-solid material was vacuum dried overnight
to obtain brown graphene oxide (GO) powder.
In situ synthesis of the Pd@rGO nanostructure
5 ml (1 mg ml1) of an aqueous suspension of GO was mixed
with 5 ml (10 mM) of an aqueous solution of Na2PdCl4 and
stirred for 10 minutes at 50 C. 1 ml (5 mM) of an aqueous
solution of L-ascorbic acid was added drop by drop to the mixed
suspension of GO and Na2PdCl4 followed by stirring for 2 h at
80 C. 500 ml (1 mM) of KCl and KBr each were added during the
reaction to prevent the agglomeration of the Pd nanoparticles.
The product was collected by centrifugation and washed with DI
water and dried. A schematic diagram related to the synthesis of
Pd@rGO is shown in Fig. 1.This journal is © The Royal Society of Chemistry 2014
Fig. 1 Schematic representation of the synthesis of the Pd@rGO
nanostructure.
Fig. 2 (i) XRD pattern, and (ii) FTIR spectrum of GO and the Pd@rGO
nanostructure.
Fig. 3 (i) SEM micrograph and (ii) TEM micrograph of the Pd@rGO
nanostructure, the red arrow shows the rGO nanosheets while
the yellow circle indicate the presence of Pd nanoparticles, (iii) EDX of
the Pd@rGO nanostructure and (iv) histogram showing the size
distribution of the Pd nanoparticles (standard deviation, s ¼ 14.47).
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View Article OnlineElectrophoretic fabrication of the Pd@rGO/ITO electrode
A lm of the Pd@rGO nanostructure was fabricated on a ITO
coated glass substrate via the electrophoretic deposition (EPD)
technique. A colloidal solution of the Pd@rGO composite
(0.5 mg dl1) in acetonitrile was used for the EPD. Electropho-
retic deposition was carried out using a two-electrode cell con-
taining the colloidal suspension by applying a DC voltage
(120 V) for 2 min. A platinum (Pt) foil (1 cm 2 cm) acted as the
cathode and a pre-cleaned ITO-coated glass substrate (sheet
resistance of 30 U cm1) as the anode. The two electrodesThis journal is © The Royal Society of Chemistry 2014separated by 1 cm were placed parallel to each other and dipped
in the colloidal suspension of Pd@rGO in acetonitrile. In order
to obtain a surface charge on the composite, 105 to 104 mol of
Mg (NO3)2$6H2O was added to the suspension as the electrolyte
for EPD. The Mg2+ ions adsorbed on the nanostructure provide
adequate positive surface charges to enable a uniform lm
deposition.30 The deposited lm was removed from the
suspension and washed with DI water followed by drying.Biofunctionalization of the Pd@rGO/ITO electrode surface
with the anti-PSA antibody
Anti-PSA antibody was covalently attached to the surface of the
Pd@rGO/ITO electrode through the formation of an amide
bond between the –NH2 groups of the antibodies and the
–COOH groups of rGO on the surface of the Pd@rGO/ITO
electrode. Prior to functionalization, the –COOH functional
groups of the Pd@rGO/ITO electrode have been activated by
well established EDC/NHS chemistry. 10 mg ml1 of an anti-PSA
antibody solution was freshly prepared in phosphate buﬀer
(PBS, pH 7.4). 10 ml of the solution of the anti-PSA antibody was
uniformly spread on the surface of the Pd@rGO/ITO electrode
and was incubated overnight in a humid chamber. A bovine
serum albumin (BSA) solution (1 mg ml1) was used to block
the non-specic active sites present on the electrode surface.
The BSA-anti-PSA/Pd@rGO/ITO immunoelectrode was washed
with PBS and stored at 4 C for further use.Results and discussion
Characterization
The synthesized Pd@rGO nanocomposite was thoroughly
characterized by X-ray diﬀraction (XRD, Rigaku), UV-Visible
(Perkin-Elmer) and Raman spectroscopy (HR800 LabRam,
Horiba/Jobin-Yvon). Structural and morphological character-
izations were carried out using scanning electron microscopy
(SEM LEO 440) and transmission electron microscopy (HRTEM,
Tecnaii-G2F30 STWIN). Electrochemical studies were con-
ducted using an Autolab potentiostat/galvanostat (Eco Chemie,
The Netherlands).XRD characterization
The crystalline structure of the Pd nanoparticles on partially
reduced graphene oxide was identied by X-ray diﬀraction
(XRD) (Fig. 2i). The intense peak at 11.4 corresponds to the
(002) reection plane and the peak at 42 corresponds to the
(001) reection plane of GO.30 It is noteworthy that the diﬀrac-
tion peak at 26.4 corresponding to graphite is very weak,
indicating the complete conversion of graphite into GO through
the oxidative treatment (Fig. 2i). The Pd@rGO spectrum reveals
diﬀraction peaks at 40, 46.5 and 67.9 indexed to the (111),
(200) and (220) crystalline planes of the faced centered cubic
structure of the Pd nanoparticles, respectively (JCPDS no.
05-0681). The absence of the peak at 11.4 corresponding to the
(002) reection plane of GO in the Pd@rGO nanostructure
indicates the conversion of GO to rGO during the synthesis. TheRSC Adv., 2014, 4, 2267–2273 | 2269
Fig. 4 (i) Electrochemical cyclic voltammograms (CV) of (a) rGO/ITO, (b) Pd@rGO/ITO, (c) anti-PSA/Pd@rGO/ITO, (d) BSA-anti-PSA/Pd@rGO/
ITO. (ii) Electrochemical impedance spectroscopy (EIS) spectra of (a) GO/ITO, (b) rGO/ITO and (c) Pd@rGO/ITO.
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View Article Onlinebroad peak at 23 is an indication of the (002) plane of reduced
graphene oxide.
FTIR studies
Fig. 2ii shows the FTIR spectra of GO and Pd@rGO. The spec-
trum of GO exhibits a band at 1620 cm1 that may be assigned
to C]C skeletal vibrations, the bands at 1748 cm1 and
1399 cm1 are due to the stretching vibration of the C]O and
C–O bonds present in the carboxylic groups. The band at
1245 cm1 is due to epoxide (C–O–C) groups, the bands at
3420 cm1, 790 cm1 and 1070 cm1 are due to the OH func-
tional groups. In Pd@rGO, the intensity of these functionalFig. 5 (i) Chronoamperometric response (at 0.3 V vs. Ag/AgCl) studies of
PSA concentration (0.01–12.5 ng ml1). (ii) Calibration plot between the
immunoelectrode. (iii) Chronoamperometric response of the BSA-anti-P
(0.01–12.5 ngml1). (iv) Calibration plot between the current and the PSA
calibration plot obtained for BSA-anti-PSA/rGO/ITO in the linear detecti
2270 | RSC Adv., 2014, 4, 2267–2273groups bands is reduced indicating the mild reduction of GO
into rGO. The XRD along with the FTIR data suggest the removal
of functional groups between the planes of GO and the
incomplete conversion of GO into rGO during the in situ
synthesis of Pd@rGO.
Structural investigations
Fig. 3i shows the typical scanning electron microscopy (SEM)
image of Pd@rGO. Fairly monodispersed Pd nanoparticles can
be seen on the surface of rGO which proves their strong aﬃnity
for rGO. Fig. 3ii shows the TEMmicrograph which supports well
the observations made through the SEM investigations. Thethe BSA-anti-PSA/Pd@rGO/ITO immunoelectrode as a function of the
current and the PSA concentration for the BSA-anti-PSA/Pd@rGO/ITO
SA/rGO/ITO immunoelectrode as a function of the PSA concentration
concentration for the BSA-anti-PSA/rGO/ITO immunoelectrode, inset:
on range (0.1–12.5 ng ml1).
This journal is © The Royal Society of Chemistry 2014
Table 1 Detection of PSA in serum samples
Sample no. 1 2 3 4 5
Amount of PSA in the serum (ng ml1) 0.20 0.20 0.20 0.20 0.20
Amount of PSA added to the serum (ng ml1) 1 2 3 4 5
Amount of PSA recorded by the
immunosensor (ng ml1)a
1.08 1.96 3.33 4.50 6.05
Recovery(%)a 108.0 98.0 111.0 115.0 121.0
a Mean of ve determinations.
Fig. 6 Schematic representation of the proposed biosensor.
Paper RSC Advances
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View Article Onlineenergy dispersive X-ray spectroscopy (EDS) measurements
conrm the presence of Pd nanoparticles in the Pd@rGO
nanostructure as shown in Fig. 3iii. The size of the Pd nano-
particles ranges from 5 nm to 10 nm, with an average size of
around 7 nm as shown in Fig. 3iv (standard deviation,
s ¼ 14.47).Electrochemical characterization
Fig. 4i shows the electrochemical cyclic voltammograms (CV) of
the (a) rGO/ITO, (b) Pd@rGO/ITO, (c) anti-PSA/Pd@rGO/ITO
and (d) BSA-anti-PSA/Pd@rGO/ITO electrodes obtained using
an Autolab potentiostat/galvanostat (Eco Chemie, The Nether-
lands) with a three-electrode system in phosphate buﬀer
saline (PBS, 50 mM, pH 7.0, 0.9% NaCl) containing 5 mM
[{Fe(CN)6}
3/4 ]. The [{Fe(CN)6}
3/4] complex is widely used as
a redox probe in electrochemical biosensors as it exhibits well
dened redox properties and cyclic voltammograms.30 It helps
for a facile electron transfer at low potentials and thus reduces
the possibility of the oxidation of other species or biomolecules
that may be present during the detection. Therefore, interfer-
ence of unwanted species can be avoided. Platinum foil (1 
1 cm2) was used as the counter electrode, Pd@rGO/ITO as the
working electrode and Ag/AgCl as the reference electrode. The
anodic peak current obtained for rGO/ITO at 3.98  104 A was
found to increase to 8.5  104 A for the Pd@rGO/ITO elec-
trode. The pronounced increment in the current value may be
attributed to the excellent electrocatalytic properties resulting
from the metallic conductivity of the Pd nanoparticles and the
synergistic eﬀects between the Pd nanoparticles and the rGO,This journal is © The Royal Society of Chemistry 2014which result in a facile electron transfer. Aer the addition of
anti-PSA, the anodic peak current of the anti-PSA/Pd@rGO/ITO
electrode decreases to 8.01  104 A compared to that of
Pd@rGO/ITO (8.5  104 A) due to the insulating nature of the
antibodies. The current is further reduced to 5.2  104 A aer
the incorporation of BSA due to the macromolecular structure
of BSA that blockmost of the non-specic active sites present on
the surface of the anti-PSA/Pd@rGO/ITO immunoelectrode. The
surface concentration (Ip) of the BSA-anti-PSA/Pd@rGO/ITO
immunoelectrode was calculated using the Brown–Anston
model (eqn (1)).
Ip ¼ n2F2 I* AV/4RT (1)
Where, n is number of electrons transferred, F is Faraday
constant (96 485.5 C mol1), I* is surface concentration
(mol cm2), A is surface area of the electrode (0.5 cm2), V is the
scan rate (50 mV s1), R is gas constant (8.134 mol1 K) and T is
the room temperature (298 K). The surface concentration of the
BSA-anti-PSA/Pd@rGO/ITO immunoelectrode was found to be
3.92  108 mol cm2. Moreover, electrochemical impedance
spectroscopy (EIS) studies were carried out to investigate the
enhanced electrochemical activity of the Pd@rGO nano-
composite (Fig. 4ii). The EIS spectra for the electrodes: (a) GO/
ITO, (b) rGO/ITO and (c) Pd@rGO/ITO were obtained using an
Autolab potentiostat/galvanostat (Eco Chemie, Netherlands)
with a three-electrode system in PBS containing 5 mM
[{Fe(CN)6}
3/4]. The charge transfer resistance (Rct) was
obtained from the diameter of the semicircle. The Rct values for
the GO/ITO, rGO/ITO and rGO@Pd/ITO electrodes were found
to be 1.79, 1.32 and 1.15 kU respectively, which indicate the
enhanced conductivity of the Pd@rGO/ITO nanocomposite
electrode compared to both the rGO/ITO electrode as well as the
GO/ITO electrode.Electrochemical response studies
Electrochemical response studies of the BSA-anti-PSA/Pd@rGO/
ITO immunoelectrode have been investigated as a function of
the antigen (PSA) concentration (0.01–12.5 ng ml1) using the
chronoamperometric method (at 0.3 V vs. Ag/AgCl) (Fig. 5i). It
has been observed that the anodic peak current decreases as a
function of the PSA concentration. It may be related to the very
large 2-D surface area of the nanostructure which provides a
suitable microenvironment for the strong covalent functional-
ization of anti-PSA on the Pd@rGO electrode surface. TheRSC Adv., 2014, 4, 2267–2273 | 2271
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View Article Onlinereduction in response current may be related to the formation
of insulating immunocomplex between Anti-PSA and PSA that
hinders electron transport. Fig. 5ii shows the calibration plot
obtained between the current and the PSA concentration. The
value of current varies linearly with the logarithm of the PSA
concentrations and obeys eqn (2).
Ip ¼ 7.8  106 (A) + 7.24  106 (A)
log[concentration (ng ml1)] (2)
Regression coeﬃcient (R2) ¼ 0.992;
The Pd@rGO based immunosensor shows a high sensitivity
of 28.96 mA ml ng1 cm2 in the linear detection range of 0.01–
12.5 ng ml1. Further, it can detect PSA at concentrations as low
as 10 pg ml1. The sensing performance of the Pd@rGO/ITO
based electrode was compared to the rGO/ITO electrode towards
PSA sensing [Fig. 5iii and iv]. The BSA-anti-PSA/rGO/ITO elec-
trode shows a sensitivity of 5.6 mA ml ng1 cm2 and it can
detect PSA at concentrations as low as 100 pg ml. The Pd@rGO/
ITO based immunosensor exhibits a higher sensitivity than the
one based on rGO/ITO which is attributed to its synergistically
improved conductivity and larger surface area. Further, the
Pd@rGO/ITO based immunosensor displays a wider linear
detection range (0.01–12.5 ng ml1) compared to that of the one
based on rGO/ITO (0.1–12.5 ng ml1). We have compared the
sensing characteristics of rGO and Pd@rGO based immunoe-
lectrodes in Table S1 in the ESI† which indicates that the
Pd@rGO/ITO based electrode shows a superior sensing perfor-
mance compared to the rGO/ITO electrode towards PSA
detection.
The reproducibility (Fig. S1, see the ESI†) of the proposed
immunosensor was investigated by measuring the CV current
response of 5 diﬀerent BSA-anti-PSA/Pd@rGO/ITO immunoe-
lectrodes prepared under the same conditions, in the presence
of 1 ng ml1 of PSA. An average current of 600 mA with a relative
standard deviation (RSD) of 3% was recorded, which indicates
an excellent reproducibility.
The specicity (Fig. S2, see ESI sheet†) of the developed
immunosenor was examined by taking the CV response current
of the immunolectrode in the presence of other interfering
molecules that are commonly found in serum such as IgG, IgM,
thrombin or lysozyme along with PSA at a 30 fold concentration.
No signicant change in the current response was appreciated
by the presence of these interfering species which shows the
high specicity of the BSA-anti-PSA/Pd@rGO/ITO immunoe-
lectrode for PSA.
In order to evaluate the feasibility of the proposed immu-
nosenor for the analysis of real biological samples, various
concentrations of PSA were added to normal serum samples
and detection was carried out with the immunosensor. Table 1
shows that the recovery of the PSA added to the serum ranged
from 99.8% to 112%, which is in acceptable range.
Further, the stability (Fig. S3, see the ESI†) of the developed
immunosensor was evaluated by storing it for 48 days in
ambient conditions. The stability of the immunosensor was
determined by measuring the CV response of the BSA-anti-PSA/2272 | RSC Adv., 2014, 4, 2267–2273Pd@rGO/ITO immunoelectrode containing 1 ng ml1 of the
PSA biomarker at regular intervals of 1 week. Only a 5%
decrease in the response current was noticed within 48 days,
which indicates its good stability. The sensing characteristics of
the proposed BSA-anti-PSA/Pd@rGO/ITO immunosensor along
with some of those reported in the literature have been
summarized in Table S1 (see the ESI†). The fabrication of the
BSA-anti-PSA/Pd@rGO/ITO based immunosensor for cancer
detection has been illustrated with the schematic diagram
shown in Fig. 6.
Conclusions
We demonstrate a facile single step method for the synthesis of
Pd@rGO with an improved conductivity and the preservation of
enough functional groups. Further, this nanostructured mate-
rial has been employed in the development of a label free
electrochemical immunosensor for ultrasensitive detection of
prostate-specic antigen, a prostate cancer biomarker. The
synthesis of Pd@rGO has been conrmed by XRD, FTIR, SEM
and TEM micrographs. Pd@rGO has been electrophoretically
deposited on an ITO coated glass electrode which was later
functionalized with anti-PSA antibodies. The electrochemical
sensing results of the proposed immunosensor indicate a high
sensitivity of 28.96 mA ml ng1 cm2 in the linear detection
range of 0.01–12.5 ng ml1. The enhanced sensitivity and
improved detection range are attributed to the synergistically
improved conductivity and the large surface area with enough
functional groups in the Pd@rGO nanostructure, which result
in high loadings of anti-PSA and enable large scale redox
conversions. The proposed immunosensor can be further
explored as a reliable point of care diagnostic tool for the
detection of other cancer biomarkers.
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